Pieris to Present at Two Upcoming Conferences - BIO-Europe Spring 2015 & the 27th Annual ROTH Conference

Download PDF

FREISING, GERMANY -- (Marketwired) -- 03/04/15 --   Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that its management will present at the BIO-Europe Spring 2015 Conference to be held at the Paris Expo - Porte de Versailles in Paris, France on Tuesday, March 10 at 5:00 PM (CET) and at the 27th Annual ROTH Conference to be held at the Ritz Carlton in Dana Point, California on Wednesday, March 11th at 8:00 AM (PT).

At BIO-Europe Spring, Eckhard Niemeier, Vice President Business Development, will present an update on the Company's inhaled IL4Ra antagonist Anticalin program for respiratory diseases. At ROTH, Stephen Yoder, President and CEO, will provide a corporate overview. A live and archived webcast of the ROTH presentation will be available on the Company's website, http://www.pieris.com.

About Pieris
Pieris is a clinical-stage biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. For more information visit www.pieris.com.

Anticalin®, Anticalins® are registered trademarks of Pieris.

Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation our Current Report on Form 8-K dated December 17, 2014.

Company Contact:
Pieris Pharmaceuticals, Inc. 
Darlene Deptula-Hicks
Chief Financial Officer 

Investor Relations Contact: 
The Trout Group
Thomas Hoffmann

Media Inquiries:
Gretchen Schweitzer
+49 172 861 8540

Source: Pieris Pharmaceuticals, Inc.